OBJECTIVE: These studies were designed to test the hypothesis that endogenous leptin, acting within the brain plays a physiologically important role in the control of food intake in lean rats. DESIGN: Antibodies directed against mouse leptin were raised in rabbits. The puri®ed IgG fractions prepared from pre-immune and immune sera were injected into the right lateral ventricle of lean Sprague-Dawley rats and obese Zucker fatty faafa rats. Changes in food intake were measured over the following 20 h period. RESULTS: The anti-leptin antibodies recognized a major epitope in the C-terminal region of the leptin molecule. The antibodies bound both mouse and rat leptin with high af®nity, but did not bind human leptin, or a selected range of other hormones and neurotransmitters known to affect food intake. In competition studies, the binding of mouse, but not human leptin to the human Ob-Rb receptor was prevented by the antibodies. This indicates that the antibodies can block the action of leptin by preventing its binding to the Ob-Rb receptor. Injection of the anti-leptin antibodies into the brain of lean rats led to an increase in food intake during the ®rst hour after injection which was not compensated during the following 19 h period. Injection of the anti-leptin antibodies did not affect food intake in Zucker fatty faafa rats which express an abnormal Ob-Rb receptor. CONCLUSION: Endogenous leptin acting within the brain plays a physiologically important role in the control of food intake in lean rats.
Introduction
Leptin, the cytokine product of the ob gene, is secreted into the blood from adipocytes. 1±3 Once released into the circulation, leptin lowers body weight by decreasing appetite and altering metabolic processes. 4±6 Injection of leptin into the ventricular system of the brain reduces food intake and increases energy expenditure, presumably by enhancing sympathetic out¯ow. 7, 8 The hypothalamus appears to be the major target tissue for the hormone since leptin receptors are present within the appetite control centers of this region. While many of the actions of leptin are mediated by central mechanisms, the presence of leptin receptors in other tissues may also suggest that this protein exerts effects on energy expenditure through peripheral sites. 9, 10 Although the exact mechanism of action has not yet been elucidated, leptin may be the long sought after satiety factor released in the periphery to regulate long-term body weight. In this lipostatic theory of body weight maintenance, as body weight increases more leptin is secreted, thereby bringing the fat mass back to a certain normal set point. In order to provide evidence for the above theory, it is necessary to show that endogenous leptin acts to suppress food intake and to enhance energy expenditure.
The objective of the present study was to test the hypothesis that endogenous leptin plays a physiologically important role in the control of energy balance by injecting polyclonal antibodies against leptin into the brain and measuring food intake. The results obtained show that endogenous leptin tonically suppresses food intake in lean animals, providing evidence for a role of this protein in the lipostatic maintenance of body weight.
Methods

Animals
The food intake experiments in these studies were conducted with obese male Zucker faafa rats (470± 600 g; Harlan, Holland) and lean male SpragueDawley rats (300±380 g; Tif: RAIf(SPF); Novartis Pharma AG, Sisseln, Switzerland). The animals were maintained in rooms with a 12 h lightadark cycle (light 04.00±16.00 h) at 20±24 C and monitored humidity. All animals were given tap water to drink and were maintained on a normal pellet diet (NAFAG, Gossau, Switzerland) for at least one week before experiment.
Production of antibodies to recombinant leptin
Polyclonal antibodies were raised in chinchilla rabbits (3 kg, Novartis) by multiple intracutaneous dorsal injections of recombinant mouse leptin (300 mga0.6 ml) supplemented with Freund's complete adjuvant (Calbiochem Corp, La Jolla, CA, USA). One month after the initial injections, the animals were boosted with leptin (300 mga0.6 ml) together with incomplete Freund's adjuvant. Blood was collected into glass tubes before the ®rst injection of leptin and again 2 and 4 weeks after the last boost. The collected blood was allowed to clot overnight at 4 C and the pre-immune and immune sera were obtained by centrifugation.
The IgG fractions from both the leptin pre-immune and immune serum samples were separated and puri®ed by a commercial application of the protein A method (Af®-Gel, Bio-Rad Laboratories, Hercules, CA, USA). The end volumes contained in each case 8±9 mgaml protein in phosphate buffered saline (PBS) containing 0.1% ascorbic acid, pH 7. Protein concentrations were assessed by a Coomassie blue method using Pierce reagent (Pierce, Rockford, IL, USA). Bovine serum albumin was used as the standard in this assay. The purity of each IgG sample was established on 12% SDS-PAGE gels.
Determination of the binding characteristics of the pre-immune and immune IgG fractions
Binding of mouse, rat and human leptin. In the food intake experiments, 10 ml of the IgG fractions, were injected directly into the right lateral ventricle of the rats. To determine the binding capacity of this volume for each IgG solution, 10 ml samples of each preparation were added to separate 100 ml solutions containing either (1±10 000 ngaml) of recombinant mouse, rat or human leptin to which 5000 cpm of the corresponding 125 I-leptin tracer had been added. The resultant solutions were incubated at 37 C for 2 h and then placed in a g-counter to measure the total counts in each tube (model 1277 Gammamaster, LKB Wallac, Turku, Finland). Thereafter, the antigenaantibody complex was precipitated with 500 ml of a solution containing 20% PEG 6000 in water and 50 ml of a solution containing 10 mgaml human g-globulin in PBS, pH 7. After mixing, the tubes were spun at 3000 g for 20 min, the supernatant aspirated and the pellet counted in a g-counter. Non-speci®c binding was determined using identical solutions that did not contain any IgG.
Binding of different peptides. To determine the speci®city of the antibodies used in these experiments, the ability of a variety of different peptides (interleukin-1b, interleukin-6, corticotropin releasing factor, neuropeptide Y, glucagon like peptide-1 and galanin) to compete with the binding of rat leptin, was assessed using the same experimental protocol described above. In these experiments 10 ml samples of the solutions of antibodies were added to 100 ml of buffer containing 5,000 cpm of 125 I-rat leptin and concentrations of the peptide under study (0.1± 1.0 mM).
Mapping epitopes on leptin. Peptides corresponding to various portions of the leptin molecule were obtained commercially (Chiron Mimotopes, Clayton, Australia and Bachem, Bubendorf, Switzerland). In addition, 2 large fragments of the mouse leptin molecule were obtained by cyanogen bromide (CNBr) catalyzed fragmentation and puri®cation, according to the following method. A solution of 1 mgaml leptin in 70% formic acid, containing 50 mg CNBr, was incubated at room temp for 3 h. The mixture was dialyzed against 20 mM Tris-HCl, pH 8 and the fragments separated using a DEAE MemSep 1000 cartridge (Millipore, Bedford, MA, USA). Absorption to DEAE was achieved with 20 mM Tris-HCl, pH 8.0 and elution with a linearly increasing NaCl gradient (100 mM ±1M). 100 ml of mouse leptin or derivative peptides at a concentration of 2 mgaml in 50 mM Na bicarbonate, pH 10.5 (coating buffer) were distributed into a 96 well plate (Nunc-Immunoplate, Maxisorp, Life Technologies, Roskilde, Denmark) and incubated overnight at room temperature. Thereafter the plate was blocked with coating buffer containing 1% gelatin. After rinsing each well with washing buffer (80 mM Na phosphate, 140 mM NaCl, 0.05% Tween 20, pH 7.2), 100 ml puri®ed anti-leptin IgG (2 mgaml in washing buffer) was added to each well and incubated for 1 h at room temperature. Following 3 washes with 300 ml of washing buffer, 100 ml of peroxidase-goat anti rabbit-IgG (dilution 1:10 000 in washing buffer; Cappel, Organon Technica, NV, Turnhout, Belgium) was added to each well and incubated for 1 h at ambient temperature. The washing procedure was repeated and 200 ml of ABTS 1 substrate was added to each well (Boehringer-Mannheim, Mannheim, Germany; 2 mM), 2.5 mM H 2 O 2 , 100 mM Na acetate, 50 mM Na 2 H 2 PO 4 , pH 4.2. After 30 min the optical density of the generated product was measured at 405 nm.
Determination of the relative af®nity of 125 I-leptin for the anti-leptin antibodies or the Ob-Rb receptor Preparation of membranes. COS-7 cells transiently expressing the human Ob-Rb receptor were washed, harvested and resuspended in ice-cold 50 mM Tris and 0.5 mM EDTA, pH 7.4. The suspension was sonicated for 25 s and centrifuged at 200 g for 10 min at 4 C. The supernatant was then centrifuged at 55 000 g for 18 min at 4 C and the resulting pellet resuspended in 50 mM Tris, 1 mM EDTA, 100 mM NaCl, pH 7.4. The membrane preparation was aliquoted,¯ash-frozen in liquid nitrogen and stored at 780 C. Shortly before use, 1% (wav) bovine serum albumin and 0.2% (wav) Tween 20 were added to the thawed samples.
Binding assay. Radiolabeled and unlabeled leptin were dissolved in distilled water. Further dilutions were in binding buffer: 50 mM Tris, 1 mM EDTA, 100 mM NaCl, 1% bovine serum albumin, 0.2% Tween 20, pH 7.4. Rabbit anti-mouse leptin IgG was diluted in PBS. Incubations were performed in Millipore Multiscreen FB ®lter plates rinsed with binding buffer before use. The following were pipetted into each well: 50 ml 125 I-leptin (®nal concentration 60± 100 pM); 50 ml binding buffer (or unlabeled human leptin for NSB); 20 ml anti-mouse leptin IgG (or PBS for the controls); 100 ml membrane suspension (6 mg protein). Incubations were performed at room temperature for 2 h. Non-speci®c binding was de®ned as the binding remaining in the presence of 1 mM human leptin. The incubations were terminated by ®ltration and the ®lters were washed and counted in a gcounter.
Intracerebroventricular cannulation
Under pentobarbital anesthesia (50 mgakg; Veterinaria AG, Zurich, Switzerland) each rat was stereotaxically implanted with an 8 mm long guide cannula (0.6 mm OD, 0.35 mm ID) aimed at the right lateral ventricle. With the incisor bar set 2 mm below the interaural line the stereotaxic coordinates used were: 70.8 mm anterior and 1.3 mm lateral to the bregma. 11 The rats were allowed 7 days of recovery during which they were handled daily to minimize nonspeci®c stress.
On the ®rst day of study, all animals received an intracerebroventricular injection of human angiotensin II (150 ngarat: Hypertensin 1 , Novartis, Basel, Switzerland). Only animals that responded with a sustained drinking response within 2 min were used in the following experiments, which were performed one week after the injection of angiotensin II.
Measurement of food intake in response to injection of antileptin antibodies
Rats were maintained in their home cages (156246 37 cm) and provided with a preweighed quantity of food which was placed on the roof grids, 10 cm from the bottom of the cage (5 pellets weighing approximately 45 g). After removal from the cages, each rat was injected intracerebroventricularly with either 10 ml of the pre-immune or immune IgG fractions, prepared as above in PBS (containing 0.1% ascorbic acid and 0.1% bovine serum albumin). The injections were performed at 08.00 h, 4 h after the beginning of the light phase. Immediately after injection, the rats were returned to their cages. After injection the food was weighed at 1, 2, 3, 4 h and then at 2 h intervals for the remainder of the experimental period.
Materials
Recombinant mouse and rat leptin were cloned and expressed by Novartis according to previously described methods. 5 Recombinant human leptin was obtained from Pepro Tech (Rocky Hill, NJ, USA). Mouse and human leptins were custom iodinated, using the lactoperoxidase method ([3-125 I-Tyr]-leptin; speci®c activity 68.1 TBqammol, ANAWA, Wangen, Switzerland). Interleukin-1b was synthesized by Novartis and interleukin-6 was obtained from Boehringer-Mannheim. Corticotropin releasing factor, galanin, glucagon like peptide-1 (GLP7-36) amide and neuropeptide Y (NPY) were obtained from Bachem.
Data analysis
Binding studies. In the binding studies the results are expressed as % BaB 0 (B 1 -NSB)a(B 0 -NSB)6100. Where B 1 the binding of iodinated leptin in the presence of cold leptin to the antibodies, B 0 the total binding of iodinated leptin in the absence of cold leptin and NSB the non-speci®c binding.
Food intake. Food intake in response to the antileptin antibodies was assessed using a cross-over block design. Lean rats or obese Zucker faafa rats were injected with the control or the anti-leptin antibodies. Seven days later, a time when food intake had returned to normal, the animals previously treated with the anti-leptin antibodies were injected with the control antibodies and vice versa. This experimental paradigm ensured that food intake in each animal was assessed in response to both the anti-leptin and the control antibodies.
Statistical analysis
Data from the food intake studies were analyzed by one way analysis of variance. Where data were followed as a function of time, the results were analyzed by analysis of variance for repeated measures. Post hoc tests following both types of analysis of variance were by unpaired t tests. Probability values less than P`0.05 were considered to be statistically signi®cant.
Results
Mapping epitopes of leptin (Table 1) The N-terminal CNBr fragment of leptin (peptide B) bound weakly to the antibodies. Mouse leptin and the C-terminal CNBr fragment (peptide A) both bound Leptin and food intake L Brunner et al strongly to the antibodies. Peptides H and J, comprising the C-terminal third of mouse leptin, produced an equivalent antigenic response, indicating that the major epitope must be present in this region. Since many peptides were studied, having overlapping sequences to this stretch of amino acids, it is possible to approximately infer the amino acid sequence containing the epitope. For example, peptide G comprising the very C-terminal portion of this sequence was inactive, indicating that the epitope does not reside in the last 27 amino acids of the molecule. Peptide I, containing a stretch of amino acids that was also present in the active C-terminal peptide, did not bind to the antibodies, indicating that the last 37 amino acids are unlikely to contain the recognition site. In addition, a peptide containing the ®rst 14 amino acids of the C-terminal fragment (peptide C) was inactive, indicating that it is also not present in this region. By inference, the most likely piece of leptin involved in binding to the antibodies is shown in bold type below.
H-YSKSCSLPQTRGLQKPESLDGVLEASLYS-TEVVALSRLQGSLQDILQQLDLSPEC-NH2.
Binding of mouse, rat and human leptin to the antileptin antibodies (Figure 1) In the following studies, 10 ml of the solution containing the anti-leptin antibodies was injected into the brain and changes in food intake measured. These experiments were performed to determine the binding capacity of this quantity of the antibodies for rat, mouse and human leptin. Since 125 I-human leptin bound to the anti-leptin antibodies with very low af®nity (`2 %) it was not possible to construct the binding inhibition curves shown in Figure 1 with this protein. The antibodies preferred mouse leptin, but also bound rat leptin with high af®nity. The quantity of antibodies studied, was able to completely trap 3 ng of mouse leptin and 1 ng of rat leptin. The antibodies prepared from pre-immune serum did not bind mouse, rat or human leptin.
At concentrations ranging from 0.1±1.0 mM none of the non-leptin peptides (interleukin-1b, interleukin-6, corticotropin releasing factor, neuropeptide Y, glucagon like peptide-1 and galanin) was able to displace the binding of 125 I rat leptin from the anti-leptin antibodies.
Determination of the relative af®nity of leptin for the anti-leptin antibodies or the Ob-Rb (Figure 2) The ability of the anti-leptin antibodies to prevent mouse leptin binding to the Ob-Rb receptor was tested in a radioreceptor assay. The antibodies were incubated at dilutions between 1:10 and 1:300 000 with 125 I-mouse leptin and human Ob-Rb receptor membranes for 2 h. The antibodies prevented binding of 125 I-mouse leptin to the human Ob-Rb receptor. A 50% inhibition of binding was achieved at an antibody dilution of 1:870. The control IgG fraction was To demonstrate that the effect was due to the antibodies binding to the radioligand and not due to an interference with the receptor itself, we performed the same experiment using 125 I-human leptin. Using this radioligand, the antibodies were inactive up to a dilution of 1:10.
Spontaneous feeding rhythms in lean rats and in obese Zucker faafa rats (Figure 3) The lean Sprague-Dawley rats used in these studies exhibited a normal feeding rhythm across both the light and dark phases of the nycthemere. In these animals, food intake occurred mainly during the dark phase, with a low level of food intake during the light phase. In contrast, the obese Zucker faafa rats exhibited a disturbed rhythm of feeding. Their food intake during the dark phase was less than that of the lean rats and they were markedly hyperphagic during the light phase. These differences in feeding rhythms were re¯ected in the calculated dark-to-light ratio of feeding between the two rat strains (lean rats 6.6 AE 0.76: faafa rats 1.96 AE 0.34; P`0.05).
Effect of leptin antibodies on feeding in lean rats and in obese Zucker faafa rats (Figure 4) Lean rats. Food intake was balanced and not signi®cantly different between the control and experimental groups of animals during the 24 h period prior to injection. Intracerebroventricular injection of control antibodies did not induce noticeable changes either in feeding behavior or feeding rhythm ( Figure  4A ). In contrast intracerebroventricular injection of antibodies directed against leptin increased food intake. Compared to control animals, food intake was signi®cantly increased during the 1 h after injection of the anti-leptin antibodies and remained signi®cantly elevated at each subsequent time point, during the course of the 20 h measurement period. There was no tendency for compensation of food intake with increasing time.
Obese Zucker faafa rats. Intracerebroventricular injection of control antibodies did not induce noticeable changes either in feeding behavior or in feeding rhythm ( Figure 4B ). In contrast to the stimulation of food intake observed in lean rats, intracerebroventricular injection of the anti-leptin antibodies to obese faafa rats did not signi®cantly affect food intake during either the light or dark phases of the nycthemere.
Comparison of food intake in response to leptin antibodies during the 6 h after injection of anti-leptin antibodies in lean and obese Zucker faafa rats ( Figure 5) Cumulative food intake 6 h after the injection of the anti-leptin antibodies is redrawn in Figure 5 for comparative purposes. The results show that the Zucker obese faafa rats were signi®cantly hyperphagic relative to normal lean rats and that their food intake was not signi®cantly affected by the anti-leptin antibodies. In contrast, food intake in lean rats treated with the anti-leptin antibodies increased signi®cantly and to the levels observed in Zucker rats during this time period.
Discussion
The purpose of these studies was to test the hypothesis that endogenous leptin acting within the brain is a physiologically important regulator of food intake in lean rats.
Initial studies sought to characterize the antibodies used in these studies. The polyclonal rabbit antimouse leptin antibodies exhibited a very low cross reactivity with human leptin (`2%). In view of the high sequence identity between mouse and human leptin, particularly in the N-terminal half of the molecule and the large homology throughout, this would not necessarily have been predicted. 1 The presence of only a few epitopes on the leptin molecule is a possible explanation for this ®nding. Assuming the peptides tested are similar in secondary structure to the corresponding sequences within the leptin protein, the following can be inferred. Since the Nterminal CNBr fragment was only moderately active and a peptide containing the ®rst 31 amino acids of mouse leptin was inactive, a minor epitope may be within the second half of this CNBr fragment. Based on the hypothetical structure of leptin, this segment would be located between helix A and helix B.
12,13
The C-terminal CNBr fragment showed marked binding to the antibodies, indicating the presence of a major epitope in this region. By studying the binding characteristics of various peptides corresponding to various amino acid stretches of this region, the most likely major epitope of leptin would be part of the random coil between helix C and helix D of the hypothetical structure of leptin. 12, 13 Interestingly, mouse and human leptin are very homologous, with the exception of the above mentioned random coil region between helix C and helix D, in which their structures diverge considerably. This could explain the difference in binding of the anti-mouse leptin antibodies to mouse and human leptin observed in these studies.
The rabbit anti-mouse leptin antibodies used in these studies bound leptin from this species with high af®nity. Although having a higher af®nity for mouse leptin, the antibodies also displayed high cross reactivity for rat leptin. Thus, these antibodies could be injected into the right ventricle of rats to determine the role of endogenous leptin in the control of food intake. Rats rather than mice were used in these experiments because, in our experience, a more reliable assessment of small changes in food intake can be obtained. The antibodies did not cross-react with a range of other peptides known to be involved in the regulation of food intake, thereby attesting to their selectivity for leptin.
Using receptor binding studies, it was demonstrated that the antibodies could bind to mouse leptin in such a way that the antibodyaantigen complex was no longer able to bind to the Ob-Rb receptor. Therefore, the anti-leptin antibodies used in these experiments should effectively antagonize the action of leptin at the Ob-Rb receptor.
In lean rats, leptin concentrations measured in the cerebrospinal¯uid during the light phase of the nycthemere range between 40±290 pgaml.
14 These values are approximately 20 times less than in the plasma, where levels of 0.6±9.8 ngaml have been recorded. 14±16 The relatively low concentration of leptin in the brain is thought to be partly due to the presence of a saturable transport system that moves leptin from the plasma into the brain. 17 Compared to lean animals, obese Zucker faafa rats have comparable levels of leptin in the cerebrospinal¯uid, but express the functional leptin receptor in reduced quantities. 18, 19 In consequence, Zucker faafa rats have been shown to be either less sensitive or unresponsive to the effects of leptin than lean animals. 20, 21 To prevent marked changes in ventricular pressure, the solution containing the pure undiluted anti-leptin antibodies was injected intracerebroventricularly in a volume of 10 ml. Based upon the bindingaaf®nity curves, this quantity of antibodies (10 mg) was able to completely bind up to 1000 pg of rat leptin. Based on the volume of the ventricular system (200 ml) and the measured leptin concentration, 14 the cerebrospinal uid of lean rats should contain between 8±58 pg leptin. Although the binding capacity of the antibodies was far in excess of the leptin present in the ventricular system of the brain, the concentration of the anti-leptin antibodies and their rate of saturation with leptin at the active sites in the hypothalamus is unknown. Therefore, the increase in food intake observed after administration of the anti-leptin antibodies may be underestimated in these studies.
Injection of the anti-leptin antibodies into the cerebrospinal¯uid led to a signi®cant increase in food intake in lean but not in obese Zucker faafa rats. This implies that the presence of leptin within the brain contributes tonically to the inhibition of food intake in lean rats. Consequently, endogenous leptin appears to play a physiologically important role in the control of food intake. Since Zucker faafa rats express a defective functional leptin receptor, the failure of the antileptin antibodies to increase food intake is expected and attests further to the speci®city of the antibodies used in these studies.
There are two ways in which leptin in plasma could enter the brain to affect food intake. Leptin may enter the brain via transport into the cerebrospinal¯uid and move from there to the interstitial¯uid. Alternatively, leptin in brain capillaries may cross the blood brain barrier to enter the interstitial¯uid directly and from there pass to the cerebrospinal¯uid. Although it is unclear at the present time how leptin enters the brain, studies of the saturable transport of insulin from plasma into the central nervous system suggest that this uptake occurs primarily into brain interstitial¯uid rather than directly into the cerebrospinal¯uid. 22 Studies with leptin are also consistent with this hypothesis. 17 In the unlikely event that the cerebrospinal uid is the route for leptin delivery to active brain sites, the action of the anti-leptin antibodies is straight forward. However, if the mechanism of leptin delivery to the brain is primarily across the blood brain barrier, with leptin in the cerebrospinal¯uid re¯ecting that which has already been cleared from brain tissue, then presumably the effect of the antisera would be to deplete brain interstitial¯uid leptin by accelerating its clearance into the cerebrospinal¯uid via an increase in the diffusion gradient. Additional studies are required to determine the exact mechanism by which antibodies interact with leptin in the brain to affect food intake.
Similar to all mammals, rodents exhibit a clear difference in the quantity of food consumed during the course of the nycthemere. On average, rats eat 80% of their daily calorie needs during the dark phase of the dark-light cycle. On the other hand, the light phase is considered to be a state of negative energy balance, during which rodents mostly sleep. The exceptions to this rule are the animal models of obesity such as faafa rats, obaob and dbadb mice which are clearly hyperphagic during the light phase. 23±27 In genetically obese rats the underlying explanation for the hyperphagia of the light phase is unknown. The results of the present studies may suggest that an absence of leptin, or a resistance to its action, may be responsible for the light phase hyperphagia observed in genetically obese animals.
Food intake during the nycthemere is divided into a number of discrete meal intervals controlled by a complex interplay of hormones and neurotransmitters. These signals are tied to the ingestion of food and determine when feeding will take place and when it will stop. 28, 29 One interesting aspect of the present studies is the failure of food intake to compensate after blockade of leptin. This observation implies that under normal conditions, leptin must exert a powerful suppressive effect on the neurotransmitters controlling food intake, not only during the light phase, but also during the dark phase of the nycthemere.
Recently a peptide antagonist of leptin has been produced by substituting an Arg to Gln at position 128 of human leptin. 30 Daily injections of this antagonist intraperitoneally in mice, lead to a continuous increase in body weight over a period of 15 days. Since in these studies food intake was not reported, it cannot be determined if the increase in body weight is due to an effect on energy intake or energy expenditure. The present studies show that blockade of the actions of leptin in the brain produce a long lasting increase in food intake, suggesting that at least part of the increase in body weight observed with the peptide antagonist may be secondary to increased food intake. Indeed, since the action of leptin in the brain is believed to be on both food intake and energy expenditure, it is likely that chronic central antibody administration would lead to an increase in body weight. The combination of the present study and that with the peptide antagonist, provide compelling evidence that leptin is a powerful endogenous regulator of food intake in lean animals.
Conclusion
Endogenous leptin present within the brain plays a physiologically important role in the control of food intake in lean rats.
